A phase I, open-label, single-dose study to evaluate the effect of mild or moderate hepatic impairment on the pharmacokinetics of fenebrutinib
-
Autoimmune Disorder -
Multiple Sclerosis (MS) -
Metabolic Disorder -
Impaired hepatic function
For the latest version of this information please go to www.forpatients.roche.com